Neogen Corporation (NEOG) β€” RQD Stock Rating Cockpit

$11.82 -3.59% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $11.72

Neogen Corporation (NEOG) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D β€’ SELL / AVOID Cap $2.58B
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NEOG Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is NEOG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Neogen Corporation (NASDAQ: NEOG) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $11.82 (-3.59% 1D, market cap $2.58B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 8/20. Across 1016 tracked Health Care issuers, NEOG ranks #302 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does NEOG compare to CLDX and NTLA in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), NEOG carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of 46.9%, and ROIC of -0.6%. By comparison, CLDX (Celldex Therapeutics Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $2.36B) and NTLA (Intellia Therapeutics Inc.) posts a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $1.75B). Among the 5-stock peer group, LNTH leads on earnings multiple (28.0x) while LNTH leads on capital efficiency (20.3% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NEOG?
β–Ό

Per NEOG's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-05-31, CIK 0000711377), Neogen Corporation generated $870.4M in revenue (-2.7% YoY), -$7.9M in net income, and $83.2M in free cash flow against $3.36B in total assets and $792.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $11.72 (-0.84%)🧬 Disciplined Float (-0.12% YoY Shares)βš™οΈ Cash Engine: 7/20 (D-) β€’ 9.6% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (47/100 Β· D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERSELL / AVOID β€’ D
025507510047
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- Β· Rk D+
Cash (7)Whales (10)SEC (10)Macro (12)CEO (8)
Each axis scored 0–20
12M PRICE TARGET CONE-5% Base Target
$15 Bull$11 Base$9 Bear
πŸ“¬ FREE NEOG RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for NEOG)Realized 20D OHLCV Swing Band: Β±9.7%
Deterministic 5-Pillar Attribution (47/100 Composite)
πŸ” WHY NEOG SCORES 47/100 (D) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Macro Regime Fit+12/20 pts (26% of score)

FRED Regime Γ— Technicals: 73% of 52W Range β€’ RSI-14 at 45.9 (NEUTRAL RANGE)

β–² #2 Bullish Driver: Whale & Options Positioning+10/20 pts (21% of score)

20D Institutional Volume Accumulation (Β±9.7% realized swing band)

β–Ό #1 Drag / Risk Factor: Cash Engine Quality7/20 pts (-13 pt drag)

Capital intensity & 0% operating margin leave 13 pts on the table

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
39
Grade E$11.73-0.1% Next Q
Q2 (-2Q)
42
Grade D$11.72+6.4% Next Q
Q3 (-1Q)
44
Grade D$12.47-5.2% Next Q
Current
47
Grade D$11.82-5.9% Hist 90D Ξ±
Trajectory: E (39) β†’ D (47)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a NEOG Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While NEOG currently carries a cautious 47/100 (D) rating due to Cash Engine Quality (7/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.24) and Max Pain ($12.41) forces dealer call-delta covering toward $14.97.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.12% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NEOGβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œNEOG Beats Next Quarter EPS Consensus (Nov 29, 2026) & Holds Above 200D SMA”
RSI-14 MOMENTUMNEUTRAL RANGE
45.930 Oversold Β· 70 Hot
ALTMAN-Z SHIELDDISTRESS RISK (<1.8)
1.45>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
7 / 99-Pt Accounting
52-WEEK LASER RANGE73% OF RANGE
L: $5$11.82H: $14
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 7 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 18 / 40
3. Hidden Risks & Market Weather● WATCH
SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 22 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on NEOG

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (35)

-0.6% ROIC with 46.9% gross margin and 3.11% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 1.45 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (50)

18/40 institutional & smart-money positioning score with 12/20 macro alignment.

Bull Case: Why Buyers Like NEOG
  • βœ“Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NEOG)

  • βœ“Walkthrough of NEOG's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
NEOG // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +30.03%β–² ASCENDING CHANNEL
2026-11-03O $12.26H $12.26L $11.82C $11.82VOL 1.95M
RES: $15.40SUP: $10.26SMA50: $12.24SMA200: $10.45
$14.73$12.77$10.81$8.85$6.89RES $15.40SUP $10.26$11.822026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NEOG Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. -2.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NEOG today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for NEOG. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NEOG today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NEOG)

1. Head-to-Head Health Care Peer Comparison (NEOG vs. CLDX, NTLA, ORKA, LNTH)

Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances (18 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Neogen Corporation (NEOG) ranks #302 by composite RQD confidence (47/100, grade D) and #217 by equity capitalization ($2.58B). Within this direct 5-issuer industry benchmark cohort, LNTH leads on earnings valuation at 28.0x trailing P/E, while LNTH leads on capital efficiency and profitability with 20.3% ROIC and 61.1% gross margin. LNTH currently holds the highest overall quantitative score in the immediate peer group at 76/100 (B+) compared with NEOG at 47/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
NEOG ACTIVE
Neogen Corporation
D 47/100 β€” 46.9% -0.6% -3.59% $2.58B Benchmark Subject
CLDX
Celldex Therapeutics Inc.
E 29/100 β€” 87.1% -35.0% +0.70% $2.36B /cldx-vs-neog β†’
NTLA
Intellia Therapeutics Inc.
E 25/100 β€” β€” -35.0% -5.74% $1.75B /ntla-vs-neog β†’
ORKA
Oruka Therapeutics Inc.
D+ 53/100 β€” β€” -18.8% +0.23% $6.41B /orka-vs-neog β†’
LNTH
Lantheus Holdings Inc.
B+ 76/100 28.0x 61.1% 20.3% +0.14% $6.56B /lnth-vs-neog β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2026-05-31 β€’ CIK 0000711377

In its most recent audited fiscal period (FY2025, filed 2026-05-31), Neogen Corporation (NEOG) reported GAAP revenue of $870.4M (-2.7% vs. FY2024 revenue of $894.7M , and -5.8% cumulative change since FY2023) , GAAP net income of -$7.9M, operating cash flow of $83.2M, and free cash flow of $83.2M (+43.0% YoY). On the balance sheet, NEOG closed FY2025 with $3.36B in total assets against $792.9M in total debt (Altman Z-Score: 1.45, Piotroski F-Score: 7/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2026-05-31 $870.4M -$7.9M $83.2M $83.2M $3.36B $792.9M
FY2024 (FY) 2025-05-31 $894.7M -$1.09B $58.2M $58.2M $4.05B $889.9M
FY2023 (FY) 2024-05-31 $924.2M -$9.4M $35.3M $35.3M β€” β€”

3. NEOG Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NEOG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Neogen Corporation (NASDAQ: NEOG) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $11.82 (-3.59% 1D, market cap $2.58B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 8/20. Across 1016 tracked Health Care issuers, NEOG ranks #302 in composite RQD confidence.

How does NEOG compare to CLDX and NTLA in the Health Care sector?

Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), NEOG carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of 46.9%, and ROIC of -0.6%. By comparison, CLDX (Celldex Therapeutics Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $2.36B) and NTLA (Intellia Therapeutics Inc.) posts a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $1.75B). Among the 5-stock peer group, LNTH leads on earnings multiple (28.0x) while LNTH leads on capital efficiency (20.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NEOG?

Per NEOG's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-05-31, CIK 0000711377), Neogen Corporation generated $870.4M in revenue (-2.7% YoY), -$7.9M in net income, and $83.2M in free cash flow against $3.36B in total assets and $792.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NEOG trading relative to its 50-day, 200-day, and 52-week technical levels?

NEOG last traded at $11.82 (-3.59% on volume of 1,947,028 shares), positioning the stock -3.43% below its 50-day simple moving average ($12.24) and +13.11% above its 200-day simple moving average ($10.45). Across its 52-week range of $5.37 to $14.26, NEOG sits at the 72.6% percentile with a 14-day RSI of 45.9 (NEUTRAL RANGE) and an implied next-earnings move of Β±9.7% ($10.67 to $12.97).

NEOG Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS β€’ SEC EDGAR Γ— CBOE Γ— FRED

Should I buy, hold, or sell NEOG stock right now?

Neogen Corporation (NEOG) currently earns a Roarable Rating of D (Sell β€” SELL) with 47/100 RQD Confidence. Stretched risk/reward at current multiples (-1% return on capital) under elevated 10-year interest-rate pressure.

What is NEOG's 12-month price target and RQD AI Jury consensus?

NEOG's 12-month base price target is $11.23 (range $8.76 to $14.97), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

ROARABLE RATING BRIEF β€’ RQD 47/100 (D) βœ“ STAGE-C NUMBER FIREWALL VERIFIED

NEOG β€” Neogen Corporation: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:25:09Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, NEOG scores 50 out of 100, grade D, labeled "Roarable Sell β€” Underperform / Distribution Warning." The five pillars are:

  • Fundamental Cash Engine: 7 / 20. Per the RQD rating, ROIC is -0.6% and FCF yield is 3.11%. This is the weakest pillar relative to its weight, reflecting that the business is not currently generating returns on invested capital above zero, even though free cash flow remains positive.
  • Whale 13F Flow: 13 / 20. Per the RQD rating, this pillar reflects institutional accumulation and options positioning. The underlying holder records are not provided in the source data, so the drivers of this score cannot be independently traced here.
  • Insider Conviction: 8 / 20. Per the RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. Individual transactions are not itemized in the source data.
  • Macro Regime Fit: 12 / 20. Per the RQD rating, beta is 1.0 and sector sensitivity is factored in. This indicates market-like sensitivity to broad moves rather than a defensive or high-volatility profile.
  • Forensic Balance Sheet: 10 / 20. Per the RQD rating, Altman Z is 1.45, Piotroski F is 7/9, and Debt/Equity is 0.38. The Piotroski reading is comparatively solid, while the Altman Z sits in a range that the source does not interpret for us.

For a prospective investor evaluating the stock today, the practical implication is that the score's weakest components (cash engine and insider conviction) point toward caution, while the balance-sheet and institutional-flow components are mixed rather than decisively negative. The overall grade reflects that the upside case must rest on an earnings or margin recovery that the current return metrics do not yet show. Valuation tradeoffs are difficult to assess because P/E and EV/EBITDA are not available in the source data; an investor cannot benchmark the current price against earnings-based multiples from this dataset alone.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$870.4M$-21.6M$-7.9MN/A$83.2M$145.3M$792.9M
FY 2024$894.7M$-1061.0M$-1092.0MN/A$58.2M$140.2M$889.9M
FY 2023$924.2M$58.6M$-9.4MN/A$35.3MN/AN/A

Per the SEC financials, revenue declined from $924.2M in FY 2023 to $870.4M in FY 2025, and operating income moved from $58.6M in FY 2023 to $-21.6M in FY 2025. The source reports a net margin of -0.9% and an operating margin of -2.5%, with a gross margin of 46.9%. Per the RQD rating, ROIC is -0.6%, and the Altman Z-Score is 1.45 and the Piotroski F-Score is 7/9; the source does not explain how these were computed. Debt of $792.9M against cash of $145.3M in FY 2025 is consistent with the reported Debt/Equity of 0.38, though the equity figure itself is not provided.

Open Questions

  • What is the composition of the reported revenue decline from $924.2M to $870.4M, and how much is attributable to specific product lines or customer segments?
  • What drove the FY 2024 net loss of $-1092.0M, and is it a non-recurring charge or a structural issue?
  • What are the EPS and P/E figures on a trailing and forward basis, given that the source data omits them?
  • What is the current share count and equity base used to derive the reported Debt/Equity of 0.38?
  • Which institutional holders and insiders account for the Whale and Insider pillar scores, and what is the direction and size of their recent transactions?

NEOG Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Neogen Corporation (NEOG) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to NEOG Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NEOG Bull vs. Bear Conversation Board β€” What's Your Call at $11.82?

πŸ‚ 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NEOG 🐻 50% BEARISH CONVICTION
1. Pick Your Side on NEOG:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk βš–οΈ DEBATE HOST 🎯 Target: $13.24 (+8.0%)
πŸ“Œ Pinned Debate

πŸ”₯ Official Bull vs. Bear Debate: Is NEOG (D β€’ RQD 50/100) a Buy at $12.26?

Welcome to the NEOG (Neogen Corporation) Roar Pit. Current RQD Composite is 50/100 (Roarable Sell β€” Underperform / Distribution Warning) in Biotechnology: In Vitro & In Vivo Diagnostic Substances. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (πŸ‚ Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $9.44 (-23.0%)
Spot @ $12.26

Pump the brakes on NEOG β€” check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on NEOG, but look at what you are paying: current EV/EBITDA multiples with 46.9% gross margins. Unless Neogen Corporation expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader πŸ‚ BULLISH 🎯 Target: $15.45 (+26.0%)
Spot @ $12.26

NEOG cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on NEOG, the market is fixating on short-term headline noise in Biotechnology: In Vitro & In Vivo Diagnostic Substances and ignoring the balance sheet and cash flow trajectory. At $12.26 (52-wk range $5.37 - $14.26), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%